Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.

MLA

Ramalingam, Suresh S., and Jennifer W. Carlisle. “Encorafenib plus Binimetinib for BRAF V600E-Mutant Metastatic NSCLC: Clinical Implications of the Phase 2 PHAROS Study.” Future Oncology, vol. 20, no. 33, Nov. 2024, pp. 2503–08. EBSCOhost, https://doi.org/10.1080/14796694.2024.2391270.

APA

Ramalingam, S. S., & Carlisle, J. W. (2024). Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study. Future Oncology, 20(33), 2503–2508. https://doi.org/10.1080/14796694.2024.2391270

Chicago

Ramalingam, Suresh S, and Jennifer W Carlisle. 2024. “Encorafenib plus Binimetinib for BRAF V600E-Mutant Metastatic NSCLC: Clinical Implications of the Phase 2 PHAROS Study.” Future Oncology 20 (33): 2503–8. doi:10.1080/14796694.2024.2391270.